CTOs on the Move

Boundless Bio

www.boundlessbio.com

 
Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.boundlessbio.com
  • 11099 North Torrey Pines Road Suite 280
    La Jolla, CA USA 92037
  • Phone: 858.766.9912

Executives

Name Title Contact Details
Jason Christiansen
 Chief Technology Officer Profile

Funding

Boundless Bio raised $46.4M on 09/19/2019
Boundless Bio raised $105M on 04/28/2021

Similar Companies

Kinnos

Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.

Beacon Food Safety

Beacon Food Safety is a Greenwood Vlg, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Primorigen Biosciences

Primorigen Biosciences LLC is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kinder Scientific

Kinder Scientific is a Poway, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CENTOGENE

CENTOGENE - transforming genetic data into medical decisions. We are one of the worldwide leaders in the field of early genetic diagnostics for rare hereditary diseases. A data repository of genetic data from over 115 countries gives us a unique access to epidemiological, clinical and genetic information on hereditary disorders, including oncogenetic indications. We focus exclusively on providing the highest quality, patient-centred service, verified by multiple international accreditations (ISO, CAP, CLIA), regular pharmaceutical audits and our outstanding short turn-around times for analysis. We believe our medical expertise is based on cutting-edge technologies including whole exome/genome sequencing, innovative biomarkers and continued R&D. Our mutation database (CentoMD®) is the worlds largest for rare genetic diseases and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation. CENTOGENE is a key partner for many high-profile pharmaceutical companies who are active in the orphan drug development.